Want to see SE:XBRANE full AI Analyst Report?
Top Page
Xbrane Biopharma AB
(XBRANE)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr14.50
▲(39.83% Upside)
Action:Reiterated
Date:10/07/26
The score is held back primarily by weak financial performance, especially significant ongoing cash burn and continued operating losses despite a healthier, low-leverage balance sheet. Technicals are a positive contributor with the stock trading well above major moving averages and positive MACD, but overbought signals (RSI/Stochastic) temper the outlook. Valuation remains constrained by negative earnings and no indicated dividend yield.
Positive Factors
Low leverage and substantial equity
Low leverage gives Xbrane more financial flexibility than a highly indebted biotech, while its substantial equity base provides support for ongoing development and commercialization. This balance-sheet position can help the company manage volatility and pursue partnerships without immediate dependence on heavy borrowing.
Negative Factors
Persistent cash burn
Ongoing negative operating and free cash flow means Xbrane is not yet funding its activities internally. Continued cash consumption can require additional financing or use of balance-sheet capacity, limiting strategic flexibility and increasing the importance of successful launches, approvals and partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and substantial equity
Low leverage gives Xbrane more financial flexibility than a highly indebted biotech, while its substantial equity base provides support for ongoing development and commercialization. This balance-sheet position can help the company manage volatility and pursue partnerships without immediate dependence on heavy borrowing.
Read all positive factors
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr278.17M
Dividend YieldN/A
Average Volume (3M)40.15K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-68.66%
EPS Growth-137.27%
CountrySE
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume74,752
30 Day Avg. Volume40,149
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr180.00M
Xbrane Biopharma AB Business Overview & Revenue Model
Company Description
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ran...
How the Company Makes Money
Xbrane makes money primarily through biosimilar-related commercialization and partnering economics. Key revenue streams can include: (1) Net sales/royalties and related commercial income from biosimilar products where Xbrane has a commercial inter...
Xbrane Biopharma AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.30M | 152.35M | 198.70M | 238.73M | 57.62M | 11.53M |
| Gross Profit | -5.12M | 74.94M | 180.47M | 35.39M | 41.04M | -684.00K |
| EBITDA | -60.62M | -16.50M | -181.97M | -282.03M | -149.34M | -168.37M |
| Net Income | -75.00M | 127.24M | -266.22M | -388.17M | -172.23M | -191.01M |
Balance Sheet | ||||||
| Total Assets | 642.61M | 671.62M | 842.43M | 653.51M | 690.51M | 688.43M |
| Cash, Cash Equivalents and Short-Term Investments | 49.50M | 86.59M | 124.33M | 65.40M | 193.99M | 295.18M |
| Total Debt | 63.71M | 58.31M | 191.72M | 231.48M | 38.22M | 44.38M |
| Total Liabilities | 103.76M | 110.97M | 633.89M | 482.17M | 265.63M | 256.69M |
| Stockholders Equity | 538.85M | 560.65M | 208.54M | 171.34M | 424.89M | 431.74M |
Cash Flow | ||||||
| Free Cash Flow | -141.35M | -390.33M | -185.97M | -423.45M | -254.04M | -296.96M |
| Operating Cash Flow | -130.31M | -250.69M | -133.73M | -406.68M | -193.92M | -219.61M |
| Investing Cash Flow | -85.17M | -37.14M | -52.25M | -16.77M | -60.13M | -77.35M |
| Financing Cash Flow | 263.19M | 255.60M | 243.62M | 298.70M | 148.86M | 349.37M |
Xbrane Biopharma AB Technical Analysis
Positive
10.37
Price Trends
10.33
Positive
10.45
Positive
9.76
Positive
Market Momentum
0.77
Negative
68.37
Neutral
85.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 10.37 is below the 20-day moving average (MA) of 11.05, above the 50-day MA of 10.33, and above the 200-day MA of 9.76, indicating a bullish trend. The MACD of 0.77 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 85.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.
Xbrane Biopharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr383.45M | 1.96 | 63.09% | ― | ― | ― | |
56 Neutral | kr3.44B | -4.25 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr278.17M | -5.57 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr189.20M | -7.83 | -56.09% | ― | ― | 14.10% | |
43 Neutral | kr1.53B | -3.05 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr61.73M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:XBRANE
Xbrane Biopharma AB
13.35
-20.03
-60.00%
SE:HNSA
Hansa Biopharma AB
35.96
-2.64
-6.84%
SE:ATORX
Alligator Bioscience AB
0.02
-0.78
-97.99%
SE:BINV
BioInvent International AB
23.05
-4.35
-15.88%
SE:ELIC
Elicera Therapeutics AB
2.77
-4.32
-60.95%
SE:CANTA
Cantargia AB
1.33
-1.18
-47.10%
Xbrane Biopharma AB Corporate Events
Xbrane bolsters biosimilar pipeline as Ximluci drives revenue and FDA review advances
Jul 17, 2026
Xbrane Biopharma reported second-quarter 2026 revenue of SEK 46.8 million, mainly from higher Ximluci product sales, alongside a negative EBITDA and a loss for the period. Despite the loss, cash and cash equivalents rose to SEK 49.5 million, and t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.